RedHill Biopharma Stock Forecast, Price & News

+0.11 (+1.71 %)
(As of 08/2/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume105,391 shs
Average Volume408,604 shs
Market Capitalization$303.89 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive RDHL News and Ratings via Email

Sign-up to receive the latest news and ratings for RedHill Biopharma and its competitors with MarketBeat's FREE daily newsletter.

RedHill Biopharma logo

About RedHill Biopharma

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focused on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 1/2a study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and Phase 2a study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-106, an encapsulated formulation for bowel preparation, which has completed Phase 2a study. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.81 out of 5 stars

Medical Sector

784th out of 2,226 stocks

Pharmaceutical Preparations Industry

382nd out of 870 stocks

Analyst Opinion: 3.5Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

RedHill Biopharma (NASDAQ:RDHL) Frequently Asked Questions

Is RedHill Biopharma a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for RedHill Biopharma in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RedHill Biopharma stock.
View analyst ratings for RedHill Biopharma
or view top-rated stocks.

What stocks does MarketBeat like better than RedHill Biopharma?

Wall Street analysts have given RedHill Biopharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but RedHill Biopharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is RedHill Biopharma's next earnings date?

RedHill Biopharma is scheduled to release its next quarterly earnings announcement on Thursday, August 12th 2021.
View our earnings forecast for RedHill Biopharma

How were RedHill Biopharma's earnings last quarter?

RedHill Biopharma Ltd. (NASDAQ:RDHL) posted its quarterly earnings results on Wednesday, May, 26th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.29. The biotechnology company earned $20.58 million during the quarter, compared to analysts' expectations of $22.37 million. RedHill Biopharma had a negative net margin of 97.62% and a negative trailing twelve-month return on equity of 251.48%.
View RedHill Biopharma's earnings history

How has RedHill Biopharma's stock been impacted by Coronavirus (COVID-19)?

RedHill Biopharma's stock was trading at $3.99 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, RDHL stock has increased by 64.2% and is now trading at $6.55.
View which stocks have been most impacted by COVID-19

What price target have analysts set for RDHL?

5 brokers have issued 1-year price objectives for RedHill Biopharma's stock. Their forecasts range from $12.00 to $26.00. On average, they anticipate RedHill Biopharma's stock price to reach $19.80 in the next twelve months. This suggests a possible upside of 202.3% from the stock's current price.
View analysts' price targets for RedHill Biopharma
or view top-rated stocks among Wall Street analysts.

Who are RedHill Biopharma's key executives?

RedHill Biopharma's management team includes the following people:
  • Mr. Dror Ben-Asher, Co-Founder, Chairman & CEO (Age 55, Pay $555.97k)
  • Mr. Micha Ben-Chorin, Chief Financial Officer (Age 52, Pay $418.05k)
  • Mr. Gilead Raday, Chief Operating Officer (Age 46, Pay $388.25k)
  • Mr. Adi Frish, Chief Corp. & Bus. Devel. Officer (Age 51, Pay $407.21k)
  • Mr. Rick D. Scruggs, Chief Commercial Officer, Head of US Operations & Director (Age 61, Pay $577.99k)
  • Mr. Ben Martie, VP, Legal Affairs
  • Ms. Valerie Graceffa, VP of Sales
  • Mr. Rob Jackson, Sr. VP of Sales & Marketing
  • Ms. Michelle Snelling, VP of HR
  • Dr. Reza Fathi, Sr. VP of R&D (Age 66)

Who are some of RedHill Biopharma's key competitors?

What other stocks do shareholders of RedHill Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other RedHill Biopharma investors own include Agenus (AGEN), Sorrento Therapeutics (SRNE), Sangamo Therapeutics (SGMO), Verastem (VSTM), Amarin (AMRN), Aralez Pharmaceuticals (ARLZ), Inovio Pharmaceuticals (INO), Tesla (TSLA), Gilead Sciences (GILD) and NVIDIA (NVDA).

What is RedHill Biopharma's stock symbol?

RedHill Biopharma trades on the NASDAQ under the ticker symbol "RDHL."

Who are RedHill Biopharma's major shareholders?

RedHill Biopharma's stock is owned by a variety of institutional and retail investors. Top institutional investors include Woodward Diversified Capital LLC (0.08%) and Cutler Group LP (0.00%).

Which institutional investors are selling RedHill Biopharma stock?

RDHL stock was sold by a variety of institutional investors in the last quarter, including Cutler Group LP.

Which institutional investors are buying RedHill Biopharma stock?

RDHL stock was acquired by a variety of institutional investors in the last quarter, including Woodward Diversified Capital LLC.

How do I buy shares of RedHill Biopharma?

Shares of RDHL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is RedHill Biopharma's stock price today?

One share of RDHL stock can currently be purchased for approximately $6.55.

How much money does RedHill Biopharma make?

RedHill Biopharma has a market capitalization of $303.89 million and generates $64.36 million in revenue each year. The biotechnology company earns $-76,170,000.00 in net income (profit) each year or ($2.10) on an earnings per share basis.

How many employees does RedHill Biopharma have?

RedHill Biopharma employs 182 workers across the globe.

What is RedHill Biopharma's official website?

The official website for RedHill Biopharma is

Where are RedHill Biopharma's headquarters?

RedHill Biopharma is headquartered at 21 Ha'arba'a Street, Tel Aviv L3, 64739.

How can I contact RedHill Biopharma?

RedHill Biopharma's mailing address is 21 Ha'arba'a Street, Tel Aviv L3, 64739. The biotechnology company can be reached via phone at 972-3541-3131 or via email at [email protected]

This page was last updated on 8/2/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.